Physician profile
Sina Tebi
NPI 1437380789
$132,912.22
in general payments reported to CMS, 2019-2025
62 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,160 · 2020: $8,067 · 2021: $21K · 2022: $32K · 2023: $35K · 2024: $11K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $19K · Travel and Lodging: $1,606 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,492.00 |
| Food and Beverage | $19,441.05 |
| Travel and Lodging | $1,606.08 |
| Education | $362.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49,755.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20,878.35 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $13,254.00 | 2019-2025 | |
| Corcept Therapeutics | $10,453.92 | 2019-2025 | Korlym |
| Mannkind Corporation | $8,962.63 | 2019-2025 | Afrezza |
| Ascendis Pharma Endocrinology INC | $6,630.91 | 2024-2025 | Yorvipath |
| Novo Nordisk INC | $4,740.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $4,731.42 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $2,020.42 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $1,350.81 | 2019-2025 | Repatha, Evenity, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $1,138.86 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $1,033.20 | 2021-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Insulet Corporation | $1,026.45 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $954.16 | 2019-2024 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $777.83 | 2019-2025 | Strensiq |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $772.22 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $704.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $348.82 | 2019-2023 | Verquvo |
| Abbvie INC. | $339.04 | 2019-2025 | Synthroid |
| Amarin Pharma, INC. | $283.13 | 2019-2023 | |
| Medtronic, INC. | $277.81 | 2021-2025 | Minimed 780g |
| Zealand Pharma US, INC. | $224.25 | 2020-2022 | |
| Esperion Therapeutics, INC. | $197.42 | 2020-2021 | |
| Sequel Med Tech, LLC | $159.94 | 2025 | Twiist |
| Beta Bionics, INC. | $158.37 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novartis Pharmaceuticals Corporation | $149.27 | 2023-2025 | |
| Ascensia Diabetes Care US INC. | $129.42 | 2021-2023 | |
| Kyowa Kirin, INC. | $128.52 | 2023 | Crysvita |
| Ars Pharmaceuticals Operations, INC. | $124.91 | 2025 | Neffy |
| Horizon Therapeutics Plc | $116.48 | 2021-2022 | |
| Cequr Corporation | $112.52 | 2023-2025 | Cequr Simplicity |
| Antares Pharma, INC. | $94.89 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Ibsa Pharma INC. | $75.48 | 2020-2025 | Flector, Licart, Tirosint |
| Tolmar, INC. | $65.08 | 2023-2025 | Jatenzo |
| Eisai INC. | $61.41 | 2019-2021 | |
| Rhythm Pharmaceuticals, INC. | $59.50 | 2025 | |
| Companion Medical, INC. | $47.68 | 2020 | |
| Shire North American Group INC | $47.16 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $45.38 | 2021 | |
| Pfizer INC. | $44.10 | 2022-2024 | |
| Amphastar Pharmaceuticals, INC. | $39.46 | 2024-2025 | |
| Valeritas, INC. | $37.35 | 2019 | |
| Glaxosmithkline, LLC. | $36.02 | 2025 | Shingrix, Arexvy |
| Neurocrine Biosciences, INC. | $31.20 | 2025 | |
| Alnylam Pharmaceuticals INC. | $29.94 | 2023 | Onpattro |
| Recordati_rare_diseases_inc. | $28.43 | 2025 | Signifor Lar |
| Medtronic Minimed, INC. | $27.73 | 2020 | |
| Madrigal Pharmaceuticals | $26.46 | 2024 | Resmetirom |
| Janssen Pharmaceuticals, INC | $25.50 | 2020 | |
| Embecta Corp. | $24.03 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ionis Pharmaceuticals, INC. | $22.65 | 2025 | Tryngolza |
| Agios Pharmaceuticals, INC. | $22.30 | 2023 | Pyrukynd |
| Senseonics, Incorporated | $22.00 | 2019 | |
| Globus Medical, INC. | $20.84 | 2025 | Senza |
| Chiesi USA, INC. | $14.83 | 2025 | Mycapssa |
| Smith+Nephew, INC. | $13.88 | 2023 | Collagenase Santyl |
| Halozyme INC | $13.13 | 2023 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$96,040.63 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sina Tebi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.